Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Oculis Holding AG Ordinary shares (OCS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/01/2025: OCS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $38.83
1 Year Target Price $38.83
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 27.24% | Avg. Invested days 44 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 990.56M USD | Price to earnings Ratio - | 1Y Target Price 38.83 |
Price to earnings Ratio - | 1Y Target Price 38.83 | ||
Volume (30-day avg) 7 | Beta 0.14 | 52 Weeks Range 10.79 - 23.08 | Updated Date 07/1/2025 |
52 Weeks Range 10.79 - 23.08 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7008.42% |
Management Effectiveness
Return on Assets (TTM) -32.13% | Return on Equity (TTM) -85.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 764100668 | Price to Sales(TTM) 1322.52 |
Enterprise Value 764100668 | Price to Sales(TTM) 1322.52 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.47 | Shares Outstanding 51033700 | Shares Floating 41222545 |
Shares Outstanding 51033700 | Shares Floating 41222545 | ||
Percent Insiders 6.35 | Percent Institutions 30.98 |
Analyst Ratings
Rating 2 | Target Price 38.83 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Oculis Holding AG Ordinary shares
Company Overview
History and Background
Oculis Holding AG is a biopharmaceutical company dedicated to developing transformative topical ophthalmic treatments. Founded in 2003 as NeuroMedix, it was later renamed to Oculis and has evolved to focus on addressing unmet needs in ophthalmology. Key milestones include clinical trials for various ophthalmic conditions and partnering with investors to take the company public in 2024 via SPAC.
Core Business Areas
- OCU-CLEN (formerly NMX-003): OCU-CLEN is a once-daily disease modifying treatment candidate for Glaucoma, that provides local anti-inflammatory and anti-fibrotic activities.
- OCU-NOV (formerly NMX-002): OCU-NOV is a novel topical ophthalmic formulation of neurotrophic factor designed to treat neurotrophic keratitis (NK).
- OCU-PLAS (formerly NMX-001): OCU-PLAS is a novel, preservative-free topical treatment candidate for Dry Eye Disease (DED) designed to address signs and symptoms of DED.
Leadership and Structure
The leadership team is comprised of Riad Sherif, MD, CEO, and other executives with experience in ophthalmology and pharmaceutical development. The organizational structure includes research, clinical development, regulatory affairs, and commercial teams.
Top Products and Market Share
Key Offerings
- OCU-PLAS: A Dry Eye Disease (DED) treatment candidate. Currently in clinical trials. Market share is not yet applicable as the product is not yet approved. Competitors include Restasis (AGN), Xiidra (NOVN), and Miebo (BXQ).
- OCU-NOV: A neurotrophic keratitis (NK) treatment candidate. Currently in clinical trials. Market share is not yet applicable as the product is not yet approved. Competitors include Oxervate (Dompu00e9 farmaceutici S.p.A.).
- OCU-CLEN: A Glaucoma treatment candidate. Currently in clinical trials. Market share is not yet applicable as the product is not yet approved. Competitors include various IOP-lowering drops (e.g., latanoprost) and surgical interventions.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical market is experiencing growth due to an aging population, increased prevalence of eye diseases, and advancements in treatment options. It is highly competitive, with both large pharmaceutical companies and smaller biotech firms vying for market share.
Positioning
Oculis Holding AG is positioned as an innovative company focused on developing topical ophthalmic treatments to address unmet needs. Its competitive advantage lies in its novel formulations and focus on treating underserved patient populations.
Total Addressable Market (TAM)
The TAM for Dry Eye Disease is estimated to be several billion dollars annually. The TAM for Neurotrophic Keratitis is smaller but still significant. Oculis is positioned to potentially capture a portion of this market with its innovative products.
Upturn SWOT Analysis
Strengths
- Novel topical ophthalmic formulations
- Focus on unmet needs in ophthalmology
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful clinical trial outcomes
- No currently marketed products
- Limited financial resources compared to larger pharmaceutical companies
- Regulatory risks associated with drug development
Opportunities
- Positive clinical trial results
- Regulatory approval of its drug candidates
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new ophthalmic indications
Threats
- Failure to achieve positive clinical trial results
- Regulatory setbacks or delays
- Competition from existing treatments
- Patent challenges
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- AGN
- NOVN
- BXQ
Competitive Landscape
Oculis Holding AG faces competition from established pharmaceutical companies with marketed ophthalmic products. Oculis's competitive advantage lies in its novel formulations and focus on unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily focused on clinical development and fundraising.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercial launch of its ophthalmic treatments. Analyst estimates vary but are generally positive.
Recent Initiatives: Recent initiatives include advancing its lead drug candidates through clinical trials and securing financing for further development.
Summary
Oculis Holding AG is a biopharmaceutical company with an experienced leadership team that has been advancing through clinical trials for ophthalmic treatments to address unmet needs. There are no current marketed products, so the future is highly dependent on successful clinical trial outcomes. Oculis's advantage is their novel topical ophthalmic formulations, but they face stiff competition. Regulatory setbacks and limited financial resources are things to watch out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Oculis Holding AG Website
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. The financial data and analysis are based on publicly available information and may be subject to change. Investments in biopharmaceutical companies are inherently risky and may result in loss of capital.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oculis Holding AG Ordinary shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-02 | CEO & Director Dr. Riad Sherif M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://oculis.com |
Full time employees 49 | Website https://oculis.com | ||
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.